Compare ProShares Ultra QQQ ETF (QLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Sana Biotechnology Inc — how do they compare? ProShares Ultra QQQ ETF trades at $98.55 (market cap $15.38B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: ProShares Ultra QQQ ETF is far larger — about 18.4× Sana Biotechnology Inc's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Sana Biotechnology Inc for 23 Days on average.
| QLD | SANA | |
|---|---|---|
Market Cap | $15.38B | $836.71M |
Volume | 4,844,085 | 4,507,444 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $5.92 |
52-Week Low | $57.16 | $2.68 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD, the ProShares Ultra QQQ ETF, trades at $98.43, down 1.8% on the day, with a bullish technical signal driven by moving averages. The ETF aims to deliver twice the daily return of the Nasdaq-100 Index. Recent news highlights its resilience compared to higher-leverage counterparts during market downturns, with institutional buying noted in Q2 2026.
The outlook hinges on Nasdaq-100 performance and Federal Reserve policy, with support at $96 and resistance at $100. Risks include market volatility and leverage decay. Analyst sentiment is mixed, advising caution until technical confirmation above key moving averages.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
